Daily non-political popular news in brief.

A gatekeeper for the US drug industry

At long last, the US is considering a government body, similar to the UK's National Institute for Health and Clinical Excellence (NICE), to review evidence on which drugs work well and whether they are cost-effective. The proposed Comparative Effectiveness Board (CEB) would review the pharmaceutical industry's hold on drug prices and stop it peddling mediocre medicines.

Read more »

Keywords: gatekeeper, drug, industry

« Previous | Next »

Similar news on "A gatekeeper for the US drug industry":

1. Lessons from Vioxx case -- New approach needed to restore faith in pharmaceutical industry
   01-19-2007 · EurekAlert!
   The pharmaceutical industry, academia and government agencies need to work together to restore faith in drug development, say doctors in this weeks' BMJ. They argue that the recent litigation over the drug Vioxx, produced by Merck and Co. Inc., has highlighted the failings of the current system, which can be open to abuse.
   Similar news · Read more »
   
2. Physician ties to drug industry stronger than ever
   04-25-2007 · EurekAlert!
   A new national survey finds that physician ties to drug manufacturers are a standard part of practice.
   Similar news · Read more »
   
3. Ghost authorship of industry funded drug trials is common
   01-15-2007 · EurekAlert!
   Ghost authorship is the failure to name, as an author, an individual who has made a substantial contribution to a scientific article. A study of 44 industry-initiated trials from Denmark in the 1990s found evidence of ghost authorship for 33 trials, which increased to 40 if a person qualifying for authorship was just acknowledged rather than being named as an author.
   Similar news · Read more »
   
4. Mayo Clinic Cancer Center -- individualizing treatment for multiple myeloma patients
   12-10-2006 · EurekAlert!
   Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells that should increase a patient's chance of responding to the agent.
   Similar news · Read more »
   
5. Drug industry increasingly influences breast cancer research
   02-26-2007 · EurekAlert!
   Breast cancer treatment trials supported by the pharmaceutical industry are more likely to report positive results than non-sponsored studies, according to a study to be published in the April 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
   Similar news · Read more »
   
6. New forecasting tool could reduce drug development costs
   02-01-2007 · EurekAlert!
   It now costs more than $800 million to develop a new drug. But what if pharmaceutical companies could predict which experimental drugs will ultimately get FDA approval, and which will ultimately fail? Researchers present a forecasting model that could potentially save hundreds of millions of dollars per new drug. They also urge more data sharing by the drug industry to improve the accuracy of forecasting, allowing more medical discoveries to be brought to the bedside.
   Similar news · Read more »
   
7. Biopharmaceutical infrastructure key to lower drug development costs
   10-11-2007 · EurekAlert!
   Improvements to the technology infrastructure for researching and developing new biopharmaceuticals would be expected to save the industry hundreds of millions of dollars annually, according to a new economic study sponsored by NIST.
   Similar news · Read more »
   
8. Drug industry spends nearly twice as much on marketing than on research and development
   01-02-2008 · EurekAlert!
   The pharmaceutical industry spends almost twice as much on the marketing and promotion of drugs than on research and development, according to a new analysis in this week's PLoS Medicine.
   Similar news · Read more »
   
9. New agreement questions NHS relation with industry
   11-16-2006 · EurekAlert!
   The Department of Health's new clinical trials agreement raises questions about the NHS's relation with the drug industry, says an editorial published in BMJ Online today.Following the tragedy of the TGN1412 trial, the Department of Health announced last month that a model clinical trials agreement has been finalised. This provides a template that can be used by all NHS trusts for any clinical trial, without modification.
   Similar news · Read more »
   
10. Nano competition debuts at Oak Ridge National Laboratory
    10-11-2006 · Oak Ridge National Laboratory (ORNL)
    A nanotechnology-oriented forum bringing together academia, industry and budding entrepreneurs, will be held April 2-4, 2007, at Oak Ridge National Laboratory.
    Similar news · Read more »